Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BYSI 
BeyondSpring Inc (BYSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: BYSI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.25
1 Year Target Price $1.25
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.06% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.07M USD | Price to earnings Ratio - | 1Y Target Price 1.25 |
Price to earnings Ratio - | 1Y Target Price 1.25 | ||
Volume (30-day avg) 1 | Beta 0.23 | 52 Weeks Range 0.98 - 3.44 | Updated Date 10/26/2025 |
52 Weeks Range 0.98 - 3.44 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.74% | Return on Equity (TTM) -310.48% |
Valuation
Trailing PE - | Forward PE 10.54 | Enterprise Value 60707913 | Price to Sales(TTM) 31.22 |
Enterprise Value 60707913 | Price to Sales(TTM) 31.22 | ||
Enterprise Value to Revenue 26.53 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 40332320 | Shares Floating 30674746 |
Shares Outstanding 40332320 | Shares Floating 30674746 | ||
Percent Insiders 15.26 | Percent Institutions 14.13 |
Upturn AI SWOT
BeyondSpring Inc
Company Overview
History and Background
BeyondSpring Inc. is a global biopharmaceutical company focused on the development of innovative cancer therapies. Founded in 2010, the company has focused on developing and commercializing plinabulin, its lead asset, and other oncology products.
Core Business Areas
- Oncology Drug Development: Focuses on developing and commercializing cancer therapies, with a primary focus on plinabulin.
Leadership and Structure
Dr. Lan Huang is the CEO and co-founder. The company has a management team focusing on research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Plinabulin: Plinabulin is BeyondSpring's lead asset, a selective immunomodulating microtubule-binding agent (SIMBA) being developed for the prevention of chemotherapy-induced neutropenia (CIN) and potential anti-cancer effects. Currently approved in China and the US. Competitors include Amgen (Neulasta, Neupogen).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies racing to develop new cancer therapies. The market is driven by unmet medical needs, technological advancements, and increasing healthcare spending.
Positioning
BeyondSpring is positioned as a company focused on innovative cancer therapies, with plinabulin as its key asset. Its competitive advantage lies in the unique mechanism of action of its drug candidates.
Total Addressable Market (TAM)
The global oncology market is estimated at several hundred billion dollars. BeyondSpring's positioning with Plinabulin allows access to a fraction of that market targeting CIN and other indications.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (Plinabulin)
- Experienced management team
- Partnerships for development and commercialization
- Approved in China
Weaknesses
- Reliance on a single key product
- Limited commercial infrastructure
- Dependence on partnerships for funding and distribution
- Financial performance
Opportunities
- Expansion into new markets
- Development of new indications for Plinabulin
- Strategic acquisitions or collaborations
- Increasing demand for innovative cancer therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
- Generic competition
Competitors and Market Share
Key Competitors
- AMGN
- SGEN
- MRTX
Competitive Landscape
BeyondSpring faces intense competition from established pharmaceutical companies with greater resources and commercial reach. Its competitive advantage lies in the novelty of its drug candidates and its focus on specific unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by clinical trial progress and regulatory milestones.
Future Projections: Future growth depends on the successful commercialization of Plinabulin and the development of its pipeline. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include seeking regulatory approvals for Plinabulin in additional markets, expanding clinical trials for new indications, and forging commercial partnerships.
Summary
BeyondSpring is a high-risk, high-reward biopharmaceutical company with a focus on oncology. The company's success hinges on the commercial success of Plinabulin and the development of its pipeline. The company needs to manage its cash flow effectively and mitigate the risks associated with clinical trials and regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), investor presentations, analyst reports, industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share figures are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BeyondSpring Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2017-03-09 | Co-Founder, Chairman & CEO Dr. Lan Huang Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://beyondspringpharma.com |
Full time employees 40 | Website https://beyondspringpharma.com | ||
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.